A Quote by Alex Azar
President Trump has exposed the dirty secret of drug pricing: There is a shadowy third player in the transaction between patients and their pharmacists: middlemen who have taken a big kickback from the drug manufacturer, which may or may not be reflected in patients' out-of-pocket costs.
Related Quotes
When the FDA forces an old drug off the market, patients have very little say in the matter. Patients have even less of a say when the FDA chooses not to approve a new drug. Instead, we are supposed to rely on the FDA's judgment and be grateful. But can the FDA really make a choice that is appropriate for everyone? Of course not.
Consider the clinicaltrials by which drugs are tested in human subjects.5 Before a new drug can enter the market, its manufacturer must sponsor clinicaltrials to show the Food and Drug Administration that the drug is safe and effective, usually as compared with a placebo or dummy pill. The results of all the trials (there may be many) are submitted to the FDA, and if one or two trials are positive—that is, they show effectiveness without serious risk—the drug is usually approved, even if all the other trials are negative.
The survival rate of Dr Burton's patients approximately doubled the maximum survival rate of conventionally treated patients. Had these findings pertained to a chemotherapy drug instead of IAT, massive amounts of funding would have been allocated to investigate the drug. Once again, the politics of cancer barred a potentially valuable treatment from reaching the public.
...In the vast majority of drug experiments, it is not uncommon for none or one or two of hundreds of patients to benefit from the drug.
PBMs claim they help patients by negotiating lower prices from drug manufacturers. But the fact is PBMs rarely, if ever, pass those savings on to patients.
Under Obamacare - which placed 159 federal agencies, commissions, and bureaucracies between patients and doctors - patients not only face dramatically higher health care costs, they've also lost the power to choose the options right for them.
We need to work on drug costs, and there's things we can work on on drug costs, especially Medicare Part D, to bring drug costs down.
The USDHEW calculates that 7% of all patients suffer compensable injuries while hospitalized .....One out of every five patients admitted to a typical research hospital acquires an iatrogenic (Caused by the treatment process) disease, one case in thirty leading to death. Half of these episodes result from complications of drug therapy; amazingly, one in ten come from diagnostic procedures.
Using prescription drug monitoring programs is an important step in identifying patients who may be improperly using prescription painkillers.
It is not enough to show that drug A is better than drug B on the average. One is invited to ask, 'For which people ("& why") is drug A better than drug B, and vice versa? If drug A cures 40% and drug B cures 60%, perhaps the right choice of drug for each person would result in 100% cures.'
Once an effective drug is approved to treat a deadly condition, introducing a second drug to treat the same disease can be hard. It's tough to recruit patients with a debilitating disease for a clinical trial when a proven medicine is already available.
To drive down high drug costs, we need to shine a light on the negotiations between drug manufacturers, middleman negotiators and pharmacies.
If anyone doubts the influence of drug company ads on patients and physicians - consider all those wasted billions of dollars for a pill that sells for more than six times as much as another drug that does the same thing, made by the same company.
The cost of prescription drugs in this country is far, far higher than in any other country. You may recall that Donald Trump as a candidate for president talked about how he was going to take on the pharmaceutical industry and it was going to lower prescription drug costs.
Lets take away the incentives to do 'to' patients and instead create incentives to do 'for' patients, to be 'with' patients. We don't need to do comparative effectiveness trials to see if that works; we can just ask patients.
When I came to Washington, I was troubled to observe so many similarities between the behaviors of drug-addicted patients and my political colleagues. In Washington power is like morphine.
Related Authors
Alexander Hamilton Quotes
American
Politician
Benjamin Franklin Quotes
American
Politician
Bernie Sanders Quotes
American
Politician
David Brooks Quotes
American
Politician
Hillary Clinton Quotes
American
Politician
Jill Stein Quotes
American
Politician
John F. Kerry Quotes
American
Politician
John McCain Quotes
American
Politician
Marco Rubio Quotes
American
Politician
Mitt Romney Quotes
American
Politician
Narendra Modi Quotes
Indian
Politician
Newt Gingrich Quotes
American
Politician
Paul Ryan Quotes
American
Politician
Rand Paul Quotes
American
Politician
Ron Paul Quotes
American
Politician
Ted Cruz Quotes
American
Politician